University Health Network (UHN) is looking for an experienced professional to fill the key role of Postdoctoral Fellow for our Bioinformatics: Translational Research In Lymphiod Malignancies Research.
Transforming lives and communities through excellence in care, discovery and learning.
The University Health Network, where “above all else the needs of patients come first”, encompasses Toronto Rehabilitation Institute, Toronto General Hospital, Toronto Western Hospital, Princess Margaret Cancer Centre and the Michener Institute of Education at UHN. The breadth of research, the complexity of the cases treated, and the magnitude of its educational enterprise has made UHN a national and international resource for patient care, research and education. With a long tradition of groundbreaking firsts and a purpose of “Transforming lives and communities through excellence in care, discovery and learning”, the University Health Network (UHN), Canada’s largest research teaching hospital, brings together over 16,000 employees, more than 1,200 physicians, 8,000+ students, and many volunteers. UHN is a caring, creative place where amazing people are amazing the world.
University Health Network (UHN) is a research hospital affiliated with the University of Toronto and a member of the Toronto Academic Health Science Network. The scope of research and complexity of cases at UHN have made it a national and international source for discovery, education and patient care. Research across UHN’s five research institutes spans the full spectrum of diseases and disciplines, including cancer, cardiovascular sciences, transplantation, neural and sensory sciences, musculoskeletal health, rehabilitation sciences, and community and population health. Find out about our purpose, values and principles here.
The Kridel lab is seeking a talented Postdoctoral Fellow to lead ongoing efforts to enhance our understanding of lymphoma pathogenesis by leveraging large datasets. The research will focus on either of the following topics: (i) dissection of immune correlates underlying both common and rare lymphoma types using single cell sequencing; (ii) development of liquid biopsy-based biomarkers for the accurate classification and monitoring of lymphoma. The post-doctoral fellow will design and carry out experiments to address key questions in the above topics and lead the writing of scientific manuscripts. The successful candidate will be embedded in a rich scientific environment that provides ample opportunities for development of technical, as well as leadership skills. Highly motivated individuals with a desire to make an impact in the field of cancer genomics are encouraged to apply.
About Our Lab
Our research is driven by the observation that the outcomes of lymphoma patients are extremely variable. Certain patients are seemingly cured, or enjoy very long remissions, while other patients experience disease relapse or refractoriness. By and large, we are currently unable to offer treatment that targets the therapeutic vulnerabilities that underlie a given patient’s lymphoma. We would like to change this. We postulate that the comprehensive deciphering of the biological underpinnings of lymphoma will lead to improved therapies for lymphoma patients. In order to achieve this goal, we are applying state-of-the-art genomic techniques to primary patient samples to unravel tumour heterogeneity and to develop novel, innovative biomarkers to predict outcome in lymphoma. Furthermore, we are leveraging novel findings from discovery platforms to elucidate mechanisms of lymphoma pathogenesis, tumour evolution and treatment resistance. Our ultimate goal is to improve patient outcomes through a better understanding of the diversity of responses to treatment and by tailoring therapy to each individual patient. See our lab website for further information: https://kridel-lab.ca/.
For representative projects, please consider the following references:
- Combined EZH2 inhibition and Ikaros degradation leads to enhanced anti-tumor activity in diffuse large B-cell lymphoma. Tong KI,* Yoon S,* Isaev K,* … Kridel R. Clinical Cancer Research 2021 Oct;27(19):5401-5414. PMID: 34168051
- Treatment resistance in diffuse large B-cell lymphoma. He MY, Kridel R. Leukemia. 2021 Aug;35(8):2151-2165.
- A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pre-transplant Deauville score. Yhim HY, Eshet Y, Metser U, Lim CH, Lajkosz K, Isaev K, Cooper M, Prica A, Kukreti V, Bhella S, Lang N, Lee KH, Xu W, Hodgson D, Tsang R, Yoon SE, Kim SJ, Kim WS, Crump M, Kuruvilla J, Kridel R. Blood Advances. 2020 Nov 24;4(22):5762-5771.
- Molecular Attributes Underlying Central Nervous System and Systemic Relapse in Diffuse Large B-cell Lymphoma. Isaev K, … Scott DW, Kridel R. Haematologica. 2021 May 1;106(5):1466-1471. PMID
- Histological Transformation and Progression in Follicular Lymphoma: a Clonal Evolution Study. Kridel R, Chan FC, Mottok A, … Gascoyne RD, Shah P. PLOS Medicine. 2016 Dec 13;13(12):e1002197. PMID: 27959929.
- Integration of Gene Mutations Improves Risk Prognostication in Patients Receiving First-line Immunochemotherapy for Follicular Lymphoma in Clinical Trial and Population-Based Cohorts. Pastore A, Jurinovic V, Kridel R, Hoster E, … Gascoyne RD, Weinstock DM, Weigert O. Lancet Oncol. 2015 Sep;16(9):1111-22. PMID: 26256760.
- Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Kridel R, Meissner B, … Weng AP, Steidl C, Gascoyne RD. Plenary Paper. Blood. 2012 Mar 1;119(9):1963-71. PMID: 22210878.
The Princess Margaret Cancer Centre (PMCC) is one of the top 5 cancer centres in the world. PMCC is a teaching hospital within the University Health Network and affiliated with the University of Toronto, with the largest cancer research program in Canada. This rich working environment provides ample opportunities for collaboration and scientific exchange with a large community of clinical, genomics, computational biology and machine learning groups at the University of Toronto and associated institutions, such as the Ontario Institute of Cancer Research, Hospital for Sick Children and Donnelly Centre.
Candidate requirements:
- PhD or MD/PhD degree in bioinformatics, computer science, statistics or molecular biology obtained within the past five (5) years
- Excellent computational skills
- Experience with cancer genomics
- Highly motivated and willing to learn
- Excellent written and verbal communication skills
- Ability to work effectively both independently and as a member of a team.
Vaccines (COVID-19 and others) are a requirement of the job unless you have an exemption on a medical ground pursuant to the Ontario Human Rights Code.
If you are interested in making your contribution at UHN, please apply on-line. You will be asked to copy and paste as well as attach your resume and covering letter. You will also be required to complete some initial screening questions.
Posting Date: March 17, 2022 Closing Date: Until Filled
More information and apply here.